CEO Gordon Sanghera on Innovation and the future of diagnostics
At the recent London Calling talk, Gordon Sanghera opened the second day of the conference with views on how a company should approach disruptive technology development and innovation.
He also spoke about how nanopore technology could change diagnostics, particularly in infectious disease. Oxford Nanopore is currently developing the 'Flongle', a 'Flow Cell Dongle' that adapts the MinION Flow cell with a low cost, reusable chip that will be particularly well suited to people who need larger numbers of individual, low cost DNA analyses while still retaining the unique real-time, ultra-long read properties of nanopore sequencing.
